America .. Researchers manage to reduce the size of the brain tumors with T -cells

Researchers from the Berlman College of Medicine at the University of Pennsylvania, USA, have managed to reduce the size of cancerous glials by targeting two proteins connected to the brain tumor, instead of one protein, using T cell therapy. The results, published in the “Nature” journal, indicated that this method reduced the size of crops within 48 hours in 6 patients with repeated, regular, repaired, regular remedial tumor. The results show that the promising strategy can effectively reduce the growth of cancerous crop, as the researchers believe that this ‘target’ approach is a very encouraging step to develop effective and long -term solid crops. Aromi dinomium and diet aromatic crop are the most aggressive type of brain tumors in adults, and are created in the form of cell growth in the brain or spicy cord. This crop grows quickly and can penetrate and destroy the body tissue. The aromatic tumor of the diet consists of cells called star cells that support neurons. The infection of the aromi -dderomic tumor can occur at any age. However, it often affects older adults and men in most cases. Symptoms of the microscopic aromatic tumor include continuous headache attacks, nausea, vomiting, vague vision or duplication and epileptic seizures. Despite aggressive therapy, which usually includes surgery and radiotherapy and chemotherapy, but the strokes are often repeated and more resistant to treatment. The methods of treating regular recurring aromatic crop usually include a multidisciplinary approach that may include additional surgery, radiotherapy, chemotherapy, targeted treatment or immune treatment, or participate in clinical trials that test experimental treatments. Usually, individuals with this kind of disease expect from 12 to 18 months after their diagnosis. The detention of T -cells, and despite research contracts, there is no treatment for these crops. The approved treatments have a limited effect on the extension of the average life expectancy of the individual, even after treatment, and when the crops return to appear, the average survival rate is no more than one year. In that clinical experiment, the researchers used a technique of immunotherapy techniques known as ‘car t’, or t cell therapy with the receptors of the chimmeric antigen, a kind of immunotherapy that includes the patient’s immune cells to better identify and attack cancer cells. The researchers who were extracted from the 6 patients, T -cells, a kind of white blood cell that plays a decisive role in the response of the immune system of infection and cancer, from the patient’s blood through a process called the white cells. In the laboratory, the researchers adapted the genetically collected T -cells to express the future of the C Gemgie (car) on the surface, and this future is designed to identify a specific protein (antigen) on the surface of the cancer cells. However, two types of protein, instead of identifying one protein, researchers have programmed T -cells to identify two ordinary protein in brain tumors, is the future of the skin growth factor (EGFR), which is estimated to be found in 60 % of all BIC crops, and the future of intercin -13 thousand 2 expressed in more than 75 % of these tumors. While the therapy is usually provided by the modified T -cells by the vein, the researchers gave the patient these double target cells through injections into the spine fluid, allowing the engineering cells to access the tumors more directly in the brain. After reaching the goal, they were associated with cancer cells, and T -cells were activated to start a strong immune response, which led to a reduction in the size of the crop. Not -homogenicity of crops, the lead author of the study, Stephen Bagli, who is an assistant professor in hematology, crops and neurosurgery, said: “This is the first time that T -cell therapy is applied with two goals, instead of only one purpose, for patients with an aromatic tumor.” He pointed out in a statement that “This is a step in the right direction. If the cells are connected by the patient’s spine fluid, the key may be to develop treatments that excel at the complicated defense systems of Biazoma.” Years ago, TT therapy was approved by the US Food and Drug Administration to fight a number of cancer, such as leukemia, but researchers have experienced problems with cell engineering to successfully search for solid crops and kill them, which constitutes the vast majority of cancer, including mugs. The challenge that researchers face in the search for a method of treating perfection Orthopedic crops and other solid crops is the lack of homogeneity of the tumor, which means that the cells in the crop are not all identical, or that they have the same antigen as the T -cells are designed to attack, and that the solid tumor is unique. As a result, the treatment that passes with one patient is not effective for another patient. Neurological toxicity, in addition; Big -Bigural tumors can evade the patient’s immune system and prevent immune cells, whether engineering cells or the immune cells of the patient who can fight against the tumor. According to the study, the sizes of crops have decreased in all six patients, and it has decreased for a few months in a subgroup of patients. Bajali pointed out that the results stimulate the research in the field of more than one protein and say: “We would like to continue our experience, giving us a better understanding of how this treatment with two -target tarry tarry tarry cells on a larger scale of individuals suffering from regular beacons.” But one of the most important problems in programmed cell therapy, especially when linked to the brain, is nerve toxicity, which occurs when a toxic substance changes the activity of the nervous system, and it can be disrupted or killed the brain cells. The researchers reported that in all the six patients treated in the treatment of T cells modified in this experiment, neuromuscular toxicity was large but controlled.